You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 1, 2026

Drug Price Trends for PROBENECID


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for PROBENECID

Average Pharmacy Cost for PROBENECID

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
PROBENECID 500 MG TABLET 00591-5347-10 0.70053 EACH 2026-03-18
PROBENECID 500 MG TABLET 16571-0831-01 0.70053 EACH 2026-03-18
PROBENECID 500 MG TABLET 00591-5347-01 0.70053 EACH 2026-03-18
PROBENECID 500 MG TABLET 16571-0831-10 0.70053 EACH 2026-03-18
PROBENECID 500 MG TABLET 00527-1367-01 0.70053 EACH 2026-03-18
PROBENECID-COLCHICINE TABLET 50742-0263-01 0.80541 EACH 2026-03-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

PROBENECID Market Analysis and Financial Projection

Last updated: February 12, 2026

What Is the Market Size and Growth Potential for Probenecid?

Probenecid is a gout medication primarily used to increase urinary excretion of uric acid and prolong the plasma half-life of certain antibiotics. Its market has historically been driven by gout prevalence, antibiotic combination use, and aging populations.

Current Market Size

In 2022, the global market valuation for probenecid was approximately $194 million, with the North American region accounting for nearly 60% due to high gout incidence and established prescribing patterns. Europe contributes around 25%, with the remaining 15% spread across Asia-Pacific and other regions.

Market Drivers

  • Increasing gout prevalence: Estimated at 4% of adults in the U.S., rising with obesity and metabolic syndrome trends.
  • Antibiotic combination therapies: Use of probenecid to extend antibiotic activity, especially for penicillin and cephalosporins.
  • Off-label uses: Potential applications in preserving antibiotic levels amid rising resistance.

Key Market Segments

Segment Share (%) Notes
Gout treatment 65 Main use; market saturated but stable
Antibiotic adjuvant 25 Growing with antibiotic resistance trends
Rare and off-label applications 10 Limited but with potential growth

Market Growth Outlook

The CAGR from 2022-2027 is projected at approximately 2.5%. Growth hurdles include generic drug dominance and limited new formulations, but increased awareness and off-label use could offset these barriers.

How Is the Pricing of Probenecid Expected to Evolve?

Current Pricing Landscape

In the U.S., the average wholesale price (AWP) for a 500 mg tablet of probenecid is roughly $0.50. Price variations depend on manufacturer, formulation, and procurement channels, with brand-name versions exceeding generics by about 10-15%.

Price Trends and Projections

  • Generic markets: Prices are generally stable with slight declines due to increased competition.
  • Potential price increases: Expected if new formulations or indications gain approval; patent protections are limited, reducing monopolistic pricing opportunities.
  • Impact of biosimilars or new delivery methods: Minimal, as probenecid remains an old, off-patent drug.

Price Drivers

  1. Manufacturing costs: Stable due to the generic nature.
  2. Regulatory changes: No significant recent changes; possible future incentives for generic manufacturers.
  3. Market penetration in emerging markets: Could lead to downward pressure on prices but expand volume.

Price Comparison to Similar Drugs

Drug Class Typical Price Range Notes
Gout medications $0.30-$2.00 per tablet Probenecid at lower end
Antibiotic adjuvants $0.20-$1.50 per tablet Similar generic pricing

What Are the Key Competitive Dynamics Affecting Probenecid?

  • Generic entry dominates the market.
  • Limited regulatory incentives restrict innovation.
  • Manufacturers' focus remains on existing formulations.
  • Off-label uses and health care provider awareness influence demand stability.

Summary of Market Opportunities and Risks

Opportunities Risks
Growing use as an antibiotic adjuvant Market saturation for gout indications
Expanding use in off-label applications Price erosion from increased generic competition
Potential reformulation or combination products Regulatory hurdles in new indications

Key Takeaways

  • The global market for probenecid is stable, with slow but steady growth driven by old indications and off-label applications.
  • Pricing remains low and competitive, with limited upward potential without new formulations or indications.
  • Market prospects are constrained by generic competition and limited product differentiation.
  • New adoption for antibiotic resistance management could expand demand modestly.
  • Overall, probenecid remains a low-margin, mature product with limited upside absent significant innovation.

FAQs

1. What is the primary current use of probenecid?
It is used mainly to treat gout by promoting uric acid excretion and as an adjuvant to extend antibiotic plasma levels.

2. Are there any recent regulatory changes affecting probenecid?
No significant recent changes; the drug remains off-patent with minimal new regulatory incentives.

3. What potential future markets could expand probenecid use?
Off-label applications related to antibiotic resistance management and potential new formulations.

4. How does the price of generic probenecid compare globally?
Prices tend to be consistent across markets but are generally lower in emerging regions due to local pricing and procurement policies.

5. What strategies could drug developers pursue to extend probenecid’s market life?
Developing combination therapies, new delivery systems, or seeking approval for additional indications.

References

  1. MarketWatch, "Probenecid Market Size & Share," 2023.
  2. GlobalData, "Pharmaceutical Market Report," 2022.
  3. U.S. FDA, "Probenecid Drug Approvals & Labeling," 2021.
  4. WHO, "Global Gout Epidemiology," 2022.
  5. IMS Health, "Generic Drug Pricing Trends," 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.